Knopp Biosciences to Present at Piper Jaffray 31st Annual Healthcare Conference

Company to provide update on status of ongoing Phase 2 clinical trial in eosinophilic asthma

PITTSBURGH, PA, NOVEMBER 12, 2019 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York, NY on December 3-5.

Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, December 3rd at 8:10 a.m. Eastern Time.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy, non-opioid treatments for pain, and other CNS hyperexcitability disorders. Please visit www.knoppbio.com

This press release contains “forward-looking statements,” including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Media inquiries:
Westwicke PR
Media:
Kate Coyle
[email protected]
203-682-8210

Surabhi Verma
[email protected]
646-677-1825

FacebookTwitterLinkedIn